THOUSAND OAKS, Calif. and LOS ANGELES, July 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Cedars-Sinai Medical Center today announced a partnership to help support the improvement of healthcare quality in the treatment of multiple therapeutic areas that could include oncology, cardiovascular disease, osteoporosis and migraine. The organizations intend to jointly undertake research projects in one or more of these therapeutic areas. They also plan to focus on projects that could achieve better clinical outcomes, experience and patient satisfaction.
Proposed initial projects under the three-year agreement focus on cancer therapies, in line with Cedars-Sinai's ranking as Southern California's largest provider of oncology services and Amgen's leadership in the field. The partnership also plans to evaluate various ways to help improve medication adherence through technological or other healthcare solutions.
Given Cedars-Sinai's No. 4 ranking nationally in the U.S. News & World Report's cardiovascular category, another joint goal of the partnership is identification of care gaps in cardiovascular disease. With heart attack and stroke on the rise nationally for the first time in a decade, the collaboration could leverage Cedars-Sinai's ability to identify patients in need of treatment using both electronic medical records, as well as the capabilities of Amgen's population health team to characterize large patient populations.
Better patient identification could support early development of preventive measures in cardiovascular disease, osteoporosis and other therapeutic areas. In many cases, the cost of preventive therapy is a fraction of the cost of an event due to the disease and valuable to the patient's health and well-being.
"This synergistic partnership between two major health care entities is devoted to furthering discovery in large populations burdened with chronic diseases," said Shlomo Melmed MB, ChB, executive vice president and dean of the Faculty at Cedars-Sinai. "We are excited to work with Amgen to help improve patient outcomes by expanding our translational and population research programs in precision medicine, care pathway redesign, diagnostic technologies and further harnessing the strength of electronic medical records."
"This agreement with Cedars-Sinai will seek to gather data about available treatment options to help improve clinical outcomes and patient experience in therapeutic areas with significant unmet need," said Peter Juhn, M.D., vice president of Global Value-based Partnerships at Amgen. "Globally, Amgen is engaged in over 75 distinct, value-based projects, spanning disease state collaborations, risk sharing and outcomes-based agreements."
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit amgen.com and follow us on twitter.com/amgen.
Cedars-Sinai is a national leader in providing high-quality, patient-centered healthcare encompassing primary care as well as specialized medicine and conducting research that leads to lifesaving discoveries and innovations. Since its beginning in 1902, Cedars-Sinai has evolved to meet the healthcare needs of one of the most diverse regions in the nation, continually setting new standards in quality and innovation in patient care, research, teaching and community service.
Today, Cedars-Sinai is widely known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai impacts the future of healthcare globally by developing new approaches to treatment and educating tomorrow's physicians and other health professionals. At the same time, Cedars-Sinai demonstrates a longstanding commitment to strengthening the Los Angeles community through wide-ranging programs that improve the health of its most vulnerable residents.
Amgen, Thousand Oaks
Kelley Davenport, 202-585-9637 (media)
Kristen Neese, 805-313-8267 (media)
Arvind Sood, 805-447-1060 (investors)
Cedars-Sinai, Los Angeles
Jonathan Diamond, 323-866-8146
View original content with multimedia:http://www.prnewswire.com/news-releases/amgen-and-cedars-sinai-partner-for-improved-healthcare-quality-300683946.html